Combivir

Combivir - the antiviral combined medicine. Lamivudin and zidovudine are highly effective selective inhibitors of HIV-1 and HIV-2. Lamivudin is a synergist of a zidovudine concerning oppression of replication of HIV.

Product dosage: 150mg+300mg
Package (num)	Per pill	Price	Buy
30	$2.87	$86.00 (0%)	🛒 Add to cart
60	$2.38	$172.00 $143.00 (17%)	🛒 Add to cart
90	$2.19	$258.00 $197.00 (24%)	🛒 Add to cart
120	$1.90	$344.00 $228.00 (34%)	🛒 Add to cart
180	$1.71	$516.00 $308.00 (40%)	🛒 Add to cart
270	$1.57	$774.00 $423.00 (45%)	🛒 Add to cart
360	$1.43 Best per pill	$1032.00 $513.00 (50%)	🛒 Add to cart

Combivir represents a cornerstone in antiretroviral therapy, combining two potent nucleoside reverse transcriptase inhibitors into a single, fixed-dose tablet. This formulation is specifically designed to streamline treatment regimens for individuals living with HIV-1 infection, enhancing adherence while maintaining robust viral suppression. By integrating lamivudine and zidovudine into one pill, it reduces pill burden and supports long-term therapeutic success. Its clinical efficacy is well-documented, making it a trusted option within combination antiretroviral strategies. Healthcare providers favor Combivir for its balance of potency, tolerability, and convenience in daily HIV management.

Features

• Fixed-dose combination tablet containing 150 mg lamivudine and 300 mg zidovudine
• Formulated for oral administration with or without food
• Manufactured under stringent quality control standards
• Available in blister packs of 60 tablets
• White, film-coated, capsule-shaped tablets imprinted with “GX CJ3”
• Stable at room temperature (15–30°C)

Benefits

• Simplified dosing: Reduces daily pill count, supporting consistent adherence to antiretroviral therapy.
• Proven viral suppression: Dual mechanism effectively inhibits HIV-1 replication, helping achieve undetectable viral loads.
• Long-term treatment sustainability: Minimizes regimen complexity, which is critical for lifelong HIV management.
• Enhanced quality of life: Fewer pills and once- or twice-daily dosing ease the daily routine for patients.
• Reduced risk of resistance: Consistent adherence lowers the probability of developing drug-resistant HIV strains.
• Well-established safety profile: Decades of clinical use provide extensive real-world data on tolerability and outcomes.

Common use

Combivir is indicated as part of combination antiretroviral therapy for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 30 kg. It is typically prescribed alongside other antiretroviral agents, such as non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or integrase strand transfer inhibitors, to form a complete suppressive regimen. Its use is guided by baseline viral load, CD4+ cell count, resistance testing, and patient-specific factors like comorbidities and potential drug interactions. Combivir is not recommended as monotherapy due to the high risk of resistance development.

Dosage and direction

The recommended dosage for adults and adolescents (weighing ≥30 kg) is one tablet taken orally twice daily. It may be administered with or without food, though consistency in timing relative to meals is advised to minimize gastrointestinal variability. For patients with renal impairment (creatinine clearance <50 mL/min), dosage adjustment is necessary, often involving separate dosing of lamivudine and zidovudine components to avoid toxicity. Hepatic impairment requires cautious use and potential monitoring. Swallow the tablet whole with water; do not crush, chew, or split. Always use Combivir in combination with other antiretroviral agents as prescribed.

Precautions

• Hematologic monitoring: Regular blood counts are essential due to the risk of anemia, neutropenia, or leukopenia associated with zidovudine.
• Lactic acidosis: Monitor for symptoms like nausea, vomiting, or abdominal pain; discontinue if suspected.
• Hepatic steatosis: Risk is increased with nucleoside analogues; liver function tests should be performed periodically.
• Exacerbation of hepatitis B: In co-infected patients, discontinuation may cause hepatitis flare; monitor liver function closely.
• Lipoatrophy: Long-term use has been associated with subcutaneous fat loss; regular body composition assessment is advised.
• Myopathy: Prolonged use may lead to myopathic changes; report unexplained muscle pain or weakness promptly.

Contraindications

Combivir is contraindicated in patients with:

• Hypersensitivity to lamivudine, zidovudine, or any component of the formulation.
• Life-threatening allergic reactions (e.g., Stevens-Johnson syndrome) to either active ingredient.
• Severe hepatic impairment or decompensated liver disease without close monitoring.
• Co-administration with stavudine due to antagonistic effects and increased toxicity risk.
• Bone marrow suppression resulting in hemoglobin <7.5 g/dL or neutrophil count <0.75 × 10⁹/L.

Possible side effect

Common adverse reactions (≥10% incidence) include headache, nausea, fatigue, and malaise. Less frequently, patients may experience:

• Anemia, neutropenia, or thrombocytopenia
• Insomnia, dizziness, or depressive symptoms
• Diarrhea, abdominal discomfort, or vomiting
• Myalgia, arthralgia, or peripheral neuropathy
• Rash or pruritus
• Elevated liver enzymes or bilirubin
• Lactic acidosis (rare but serious)
• Lipodystrophy or fat redistribution

Drug interaction

Combivir interacts with several classes of medications:

• Ganciclovir/valganciclovir: Increased risk of hematologic toxicity.
• Ribavirin: Antagonistic effect with zidovudine; avoid concomitant use.
• Doxorubicin: May inhibit intracellular activation of zidovudine.
• Stavudine: Pharmacologic antagonism; contraindicated.
• Nephrotoxic agents (e.g., aminoglycosides): May exacerbate renal effects.
• Probenecid: Reduces glucuronidation of zidovudine, increasing exposure.
• Other myelosuppressive drugs: Additive risk of bone marrow suppression.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Consistent adherence is critical to maintaining viral suppression and preventing resistance; consider using pill organizers or digital reminders to support routine.

Overdose

Symptoms of overdose may include nausea, vomiting, lethargy, and hematologic disturbances such as profound anemia or neutropenia. Hemodialysis may enhance elimination of lamivudine but is less effective for zidovudine. Treatment is supportive and symptomatic; monitor hematologic parameters closely and administer transfusions or growth factors if indicated. There is no specific antidote. Contact a poison control center or seek emergency medical attention immediately.

Storage

Store Combivir tablets at room temperature (15–30°C) in the original blister pack or container to protect from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Avoid storing in bathrooms or other humid areas. Discard any unused medication via take-back programs or following local guidelines; do not flush.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or modifying any medication regimen. Individual patient needs may vary based on clinical status, comorbidities, and treatment history. The prescribing information provided here is a summary; refer to the full manufacturer’s labeling for comprehensive details.

Reviews

Clinical studies and long-term observational data consistently support the efficacy and tolerability of Combivir as part of combination antiretroviral therapy. In randomized trials, it demonstrated non-inferiority to separate component dosing, with high rates of viral suppression and CD4+ recovery. Patient-reported outcomes highlight appreciation for reduced pill burden and convenience. Some critiques note older nucleoside analogues like zidovudine may be associated with more side effects compared to newer agents, though Combivir remains a viable option in specific clinical scenarios. Overall, it is regarded as a reliable and well-characterized component of HIV management.